| Name | Title | Contact Details |
|---|
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
isotechnika is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Concord is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A physician led and owned organization committed to improving healthcare by supporting independent rheumatology practices across the nation and providing innovative technology to lower healthcare costs for providers and patients
NXT USA is a company that focuses on developing clinically validated branded ingredients that positively impact global health.